Elevation Oncology (NASDAQ:ELEV) Given “Outperform” Rating at Wedbush

Wedbush restated their outperform rating on shares of Elevation Oncology (NASDAQ:ELEV) in a research report sent to investors on Friday morning, Benzinga reports. Wedbush currently has a $8.00 price objective on the stock.

A number of other analysts have also issued reports on ELEV. HC Wainwright reiterated a buy rating and set a $6.00 price target on shares of Elevation Oncology in a research note on Tuesday, April 9th. JMP Securities reaffirmed a market outperform rating and set a $7.00 target price on shares of Elevation Oncology in a research note on Thursday, March 7th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of Buy and a consensus price target of $7.25.

Elevation Oncology Trading Up 1.1 %

Shares of ELEV opened at $3.74 on Friday. The company has a current ratio of 46.22, a quick ratio of 46.22 and a debt-to-equity ratio of 0.41. The firm has a 50-day moving average price of $4.38 and a 200 day moving average price of $2.42. Elevation Oncology has a 12-month low of $0.36 and a 12-month high of $5.89. The firm has a market capitalization of $204.35 million, a P/E ratio of -3.60 and a beta of 1.52.

Elevation Oncology (NASDAQ:ELEV) last released its quarterly earnings results on Wednesday, March 6th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.02. Sell-side analysts forecast that Elevation Oncology will post -0.87 EPS for the current year.

About Elevation Oncology

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.